Hugel Expects Acquisition By GS Consortium Won’t Deter Growth Strategy

$1.46bn Deal Biggest Ever In Korean Biopharma

 
• By Jung Won Shin

Hugel says its longer-term global growth strategy will remain intact after a major acquisition of the Korean medical aesthetics company by a consortium including GS Group.

botulinum toxin
GS-CBC Consortium Becomes Largest Shareholder Of Hugel • Source: Alamy

More from South Korea

More from Focus On Asia